Table 3.
Changes in treatment during follow up, as a proportion of treatment periods
| Arginine (n = 55) | Citrulline (n = 32) | Arginine + citrulline (n = 60) | Total (n = 147) | |
|---|---|---|---|---|
| Treatment switched at end of treatment perioda | 41 (74.5) | 13 (40.6) | 21 (35.0) | 75 (51.0) |
| Treatment(s) switched to: | ||||
| Arginine | – | 2 (15.4) | 6 (28.6) | 8 (10.7) |
| Citrulline | 4 (9.8) | – | 11 (52.4) | 15 (20.0) |
| Arginine + citrulline | 36 (87.8) | 5 (38.5) | – | 41 (54.7) |
| No arginine or citrulline | 1 (2.4) | 6 (46.2) | 4 (19.0) | 11 (14.7) |
Data are shown as number (%) of treatment periods
aTreatment periods were defined as a time interval receiving arginine alone, citrulline alone or arginine combined with citrulline, with no change in drug regimen (i.e., stopping or (re)introducing citrulline or arginine). There were a total of 147 treatment periods in the exposed population